Main Therapeutic Uses and Benefits of Angiovit

Angiovit is a specialized vitamin complex primarily designed to manage elevated levels of homocysteine in the blood, a condition known as hyperhomocysteinemia. By providing a specific combination of B-group vitamins, the supplement supports metabolic processes essential for cardiovascular and neurological health.

Cardiovascular Support

The primary application of Angiovit is in the prevention and adjunct treatment of various cardiovascular pathologies. It is frequently utilized in the following contexts:

• Ischemic Heart Disease: Helping to stabilize metabolic processes within the cardiac muscle.
• Atherosclerosis: Supporting the integrity of the vascular endothelium and slowing the progression of arterial plaque formation.
• Circulatory Disorders: Improving blood flow and reducing the risk of thrombosis related to high homocysteine levels.

Neurological and Systemic Health

Beyond its cardiovascular applications, Angiovit plays a role in maintaining the health of the nervous system and supporting systemic metabolic functions:

• Cerebrovascular Health: It is used to support brain circulation and reduce the risk of stroke or chronic cerebral ischemia.
• Diabetic Complications: The supplement is often included in management plans for diabetic angiopathy to help protect blood vessels from damage.
• Pregnancy Support: In obstetric practice, it may be used to address hyperhomocysteinemia, which is associated with placental insufficiency and other pregnancy-related complications.

Key Benefits of the Formulation

The effectiveness of Angiovit is rooted in the synergistic action of its components, which facilitate the conversion of homocysteine into safer amino acids like methionine and cysteine. This biochemical regulation provides several key benefits:

• Vascular Protection: By lowering homocysteine, the supplement helps prevent the oxidative stress and inflammation that damage the inner lining of blood vessels.
• Metabolic Optimization: It supports the fundamental methylation cycle, which is vital for DNA repair and neurotransmitter synthesis.
• Comprehensive Vitamin Support: It addresses specific vitamin deficiencies that can lead to anemia and impaired nerve function.

Regulatory References

1. FDA-verified B-Complex Indications (PDF)

Who Can and Cannot Use Ангиовит?

Regulatory authorities define the population eligibility for Ангиовит (Pyridoxine, Folic Acid, and Cyanocobalamin) through strict contraindications and conditional use warnings.

---

Prohibited Use (Contraindications)

Use of this medicine is formally contraindicated in two key patient groups:

• Individuals with known Hypersensitivity or allergy to any component of the formulation.
• Patients diagnosed with Leber's Hereditary Optic Atrophy, as the Cyanocobalamin ( B12) component may accelerate nerve damage.

---

Condition-Specific Restrictions

Eligibility is limited by specific medical conditions. The medicine must not be used in cases of Undiagnosed Anemia or as the sole treatment for Pernicious Anemia. This is because the Folic Acid ( B9) component can mask the critical hematological signs of a B12 deficiency while irreversible neurological damage progresses. Caution is also mandated for patients with impaired kidney function due to the potential for aluminum accumulation associated with the B12 component.

---

Age and Life-Stage Eligibility

The formulation is intended for use in the Adult population. Use in Pediatric patients is generally not established by regulatory bodies. Eligibility during Pregnancy and Lactation is possible but is considered conditional, requiring clinical oversight and adherence to specific dosage precautions established in official labeling.

Interactions with other medicines and products

This B-vitamin complex (Pyridoxine, Folic acid, Cyanocobalamin) may engage in specific interactions with certain medicinal products and substances, as formally documented by regulatory authorities. The interaction profile highlights effects on both the B-vitamin component exposure and the efficacy of co-administered medicines.

Drug Interactions

Classification	Interacting Agents	Official Statement of Interaction
Pharmacodynamic	Levodopa	Pyridoxine (B6) is documented to reverse the therapeutic efficacy of Levodopa, an effect mitigated when Levodopa is combined with a peripheral decarboxylase inhibitor.
Reduced Co-Drug Levels	Phenytoin, Phenobarbital	Pyridoxine (B6) may accelerate the metabolism of these anticonvulsants, resulting in reduced serum concentrations and potentially diminished therapeutic levels.
Reduced B-Vitamin Exposure	Methotrexate	This agent acts as a folic acid antagonist, officially described as reducing the effective availability of Folic acid (B9).
Reduced B-Vitamin Absorption	Oral Contraceptives	Use of certain oral contraceptives may reduce the plasma concentration of Pyridoxine (B6) and Folic acid (B9).
Reduced B-Vitamin Absorption	Gastric Acid Reducers	Long-term use of proton pump inhibitors or H2-receptor antagonists may reduce the absorption of Cyanocobalamin (B12).

Substance Interaction

Alcohol (Ethanol): Chronic consumption of alcohol is officially documented to reduce the absorption and status of both Pyridoxine (B6) and Folic acid (B9).

The mechanism of Ангиовит relies on the coordinated action of its three B-vitamin components ( B6, B9, B12) to optimize central metabolic pathways, influencing systemic physiological markers.

---

Enhanced Enzymatic Clearance of Homocysteine

The core action involves supplying obligatory cofactors to two critical enzymes: Methionine Synthase (MTR), supported by B9 and B12, and Cystathionine beta-synthase (CBS), supported by B6. This cofactor provision restores the full catalytic capability of the enzymes, enabling the accelerated conversion of the substrate, Homocysteine, into Methionine and Cystathionine.

---

Dual-Pathway Synergy and Metabolic Support

The combination provides a dual-pathway approach, supporting both the Remethylation and Transsulfuration routes for Homocysteine catabolism simultaneously. This functional synergy promotes the efficient processing of the amino acid, contributing to a reduction in its plasma concentration. This metabolic correction indirectly facilitates the production of Methionine, which is required for numerous downstream cellular methylation reactions.

---

Mitigation of Vascular Biochemical Stress

The resultant lowering of circulating Homocysteine activates a crucial mechanistic cascade. Reduced Homocysteine concentrations mitigate the pro-oxidative and pro-inflammatory biochemical stress mediated by this substrate on the endothelium, the lining of the blood vessels. This change influences the functional state of the vascular system by reducing the biochemical burden.

How to Use Ангиовит: Official Administration Guidelines

This section details the authorized principles for administering the medication, focusing strictly on dosing and procedural requirements.

---

Administration Scope

Feature	Guideline
Route of administration:	Oral route only, consistent with its form as a film-coated tablet.
Dosing schedule (Adults):	The standard regimen is a fixed dose of one tablet daily (1 таб./сут). The fixed combination contains 5 mg Folic acid, 4 mg Pyridoxine hydrochloride, and 0.006 mg Cyanocobalamin.
Timing in relation to meals:	Administration is permitted irrespective of food intake (вне зависимости от приема пищи), offering flexibility in daily scheduling.
Preparation requirements:	The film-coated tablet must be swallowed whole and does not require dilution or special preparation before use.
Age-group administration rules:	The product is contraindicated for use in children (детский возраст). Use during pregnancy requires mandatory medical recommendation, and use during breast-feeding is not recommended.

---

Resulting Procedural Structure

The official instruction defines the overall use as a time-limited course. The duration of the treatment course is generally specified as 20 to 30 days. The decision to repeat the course is reserved exclusively for the prescribing physician.

---

Connection to the Overall Use Protocol

The official instructions establish a fixed, once-daily oral routine that simplifies adherence by allowing flexibility around mealtimes. This structure standardizes the application of the high-dose vitamin B complex over a defined period, ensuring that both the initiation and any subsequent cycles of treatment are governed by the specific duration parameters set forth in the documentation.

Research Evidence / Overview of Studies for Ангиовит

Evidence for Regulating Homocysteine Levels

Research has explored the B-vitamin combination (Vitamins B6, B9, and B12) primarily through Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews focusing on the biomarker homocysteine. Studies consistently reported measurements of reductions in plasma Hcy levels following administration. However, research examining clinical vascular events (e.g., stroke, heart attack) described findings that were mixed across different large meta-analyses and trials. Certainty remains low regarding whether the observed biomarker shifts translate into consistent, long-term clinical change across all groups.

Evidence for Symptomatic Nerve Support and Deficiency

The combination was studied for its use in conditions presenting with nerve discomfort using clinical trials and neurophysiological studies. Trials monitored patient-reported outcomes describing perceived discomfort and functional measures. Data show patterns related to improvements in subjective pain ratings in some studied cohorts, although data for certain groups remain insufficient.

Separately, the use for Preventing B-Vitamin Deficiencies relies on extensive Systematic Reviews and Nutritional Studies which consistently reported the correction and maintenance of blood concentrations of the required vitamins. This evidence contributes to the broader landscape that acknowledges the fundamental necessity of these micronutrients.

Research Gaps and Uncertainties

The research highlights key limitations, including the inconsistent findings when attempting to link homocysteine lowering directly to specific, long-term clinical change. Evidence quality varies across studies, leading to conflicting results in meta-analyses about the potential for event reduction. Furthermore, there is limited comparative evidence to demonstrate a clear advantage of this specific triple combination over single-vitamin replacement therapies, and long-term outcomes for specific patient populations are not fully established.

Key Studies & References

1. B-Complex Indications (Product Information Leaflet DRP-3602-04)

Common questions about Ангиовит (FAQ)

---

Q: What should I do if I accidentally miss a day's dose?

If a dose is remembered on the same day as scheduled, it may still be taken. If the dose is not remembered until the next day, official guidance recommends omitting the missed dose entirely. The subsequent dose should be taken at the usual scheduled time, and taking a double dose to compensate for a missed dose is not recommended in the official guidance.

---

Q: Are there any dietary restrictions I need to follow while taking this medication?

Official product information on substance interactions specifically notes the potential for interference with alcohol. Official documentation indicates that chronic consumption of alcohol may reduce the absorption and status of both the Pyridoxine ( B6) and Folic acid ( B9) components.

---

Q: What are the symptoms of a B12 deficiency that Folic acid can mask?

Regulatory safety warnings indicate that Folic acid can correct the blood-related signs (anemia) caused by a B12 deficiency, potentially masking this key indicator. This masking effect is a concern because neurological damage may continue to progress. This progression can potentially involve symptoms such as persistent tingling, numbness (paresthesia), memory issues, and changes in coordination.

Storage and Disposal Requirements for Ангиовит

Official regulatory documentation specifies the mandatory environmental conditions and handling rules for storing Ангиовит film-coated tablets. The product must be stored at a temperature not exceeding 25 C.

To maintain the product's stability and its 3-year shelf-life, the tablets must be kept in a dry place and protected from light.

Storage Restriction	Requirement
Temperature Limit	Do not store above 25 C
Environmental Control	Protect from light and moisture
Shelf-Life	3 years (Do not use after expiration)

Furthermore, all official labeling requires that the medication be stored in a location that is inaccessible to children (out of the sight and reach of children). Disposal of expired or unused tablets should be carried out according to local governmental regulations for pharmaceutical waste; the product must not be used beyond the specified expiration date.